Octapharma AG
http://www.octapharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Octapharma AG
Alentis Adds To Bank Balance And Rides The Claudin Wave
While most of the R&D attention in the hot space of claudins has focused on targeting CLDN18.2, the Swiss biotech believes its CLDN1 programs have the advantage of a broader expression profile.
Finance Watch: Insilico Raises $255m To Take AI-Discovered Drugs Into The Clinic
Private Company Edition: Nine new venture capital mega-rounds include Insilico’s series C, $250m from Blackstone for a CAR-T therapy spinout from Intellia and a $210m series B round for Umoja.
Alentis Aims To Put The Brakes On Fibrosis
Building on 20 years of work and positive preclinical data, and backed by a fresh injection of cash, Alentis is taking its liver fibrosis candidate into Phase I trials in the fourth quarter.
Coronavirus Update: EU Regulator Skeptical On Vaccine This Year, Takeda Prepares Hyperimmune Alliance
EMA leader doesn't share Oxford's optimism, Takeda-led alliance forges ahead with plasma-derived therapy plans, Indian pharma firm Cadila gets into testing kits.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice